期刊文献+

计算机辅助筛选酪氨酸激酶相关蛋白TRP-2 CTL模拟表位 被引量:1

Computer Aided Screening of Tyrosinase Related Protein-2 (180~188) Mimotope
下载PDF
导出
摘要 运用多项式方案、量化基序方案等经典的CTL表位筛选方案,初步筛选了酪氨酸激酶相关蛋白TRP-2 CTL表位TRP-2_(180~188)(SVYDFFVWL)的模拟表位,以通过表位改造提高其与HLA-A2.1分子结合的能力,从而提高其免疫原性,根据打分结果,合成了4个得分较高的九肽序列,亲和力实验结果表明所筛选的4个序列较原序列均有较高的亲和力,但对2位的单突变结果较1和2位双突变结果理想,进一步运用分子模拟方法对4个序列与HLA-A2.1分子间的相互作用进行了分子模拟分析,分子模拟结果较好地解释了上述实验现象,从而为进一步的结构改造提供了理论依据,本研究提供了一个合理高效的模拟表位筛选方法。 To enhance HLA-A2.1 molecule affinity and immunogenicity of the tyrosinase related protein-2 (180~188) epitope, the classical epitope prediction methods including the polynomial method and the quantitative motif method were used to predict the modified epitope. Then four altered peptide ligands (APLs) with high score were synthesized, and their affinity with HLA-A2.1 molecule was assayed. The results show that the four APLs have high affinity, but the results of single mutant at P2 are better than those of double mutant at P1 and P2. So the molecular modeling was performed to study the interaction between the APLs and HLA-A2 molecule, and the results give a rational reason for the experimental results and provide the theoretical base for the further structure modification. This study provides a rational and high efficiency method to screen mimotope.
出处 《化学学报》 SCIE CAS CSCD 北大核心 2007年第8期760-764,共5页 Acta Chimica Sinica
基金 国家自然科学基金(Nos.30471579.30571714.2001CB510001) 新世纪优秀人才支持计划资助项目。
关键词 酪氨酸激酶相关蛋白 模拟表位 分子模拟 计算机辅助筛选 免疫原性 tyrosinase related protein-2 mimotope molecular modeling
  • 相关文献

参考文献16

  • 1Bloom,M.B.; Perry-Lalley,D.; Robbins,P.F.; Li,Y.;el-Gamil,M.; Rosenberg,S.A.; Yang,J.C.J.Exp.Med.1997,185,453.
  • 2Parkhurst,M.R.; Fitzgerald,E.B.; Southwood,S.; Sette,A.; Rosenberg,S.A.; Kawakami,Y.Cancer Res.1998,58,4895.
  • 3Harada,M.; Yamada,H.; Tatsugami,K.; Nomoto,K.Immunology 2001,104,67.
  • 4Pittet,M.J.; Valmor,D.; Dunbar,P.R.; Daniel,E.; Speiser,D.E.; Lienard,D.; Lejeune,F.; Fleischauer,K.; Cerundolo,V.; Cerottini,J.C.; Romero,P.J.Exp.Med.1999,190,705.
  • 5Snyder,J.T.; Alexander,M.A.; Berzofskyl,J.A.; Belyakov,I.M.Curr.HIV Res.2003,1,287.
  • 6Ruppert,J.; Sidney,J.; Celis,E.; Kubo,R.T.; Grey,H.M.;Sette,A.Cell 1993,74,929.
  • 7Tourdot,S.; Scardino,A.; Saloustrou,E.; Gross,D.A.;Pascolo,S.; Cordopatis,P.; Lemonnier,F.A.; Kosmatopoulos,K.Eur.J.Immunol.2000,30,3411.
  • 8Gulukota,K.; Sidney,J.; Sette,A.; De DeLisi,C.J.Mol.Biol.1997,267,1258.
  • 9Parker,C.E.; Nightingale,S.; Taylor,G.P.; Weber,J.; Bangham,C.R.J.Virol.1994,68,2860.
  • 10Rener,M.; Claesson,M.H.; Bregenholt,S.; Ropke,M.Exp.Clin.Immunogenet.1996,13,30.

同被引文献13

  • 1郭义,郭卫,汤小东,高占成,何湘君.尤文肉瘤基因免疫治疗的研究[J].中华实验外科杂志,2004,21(7):848-851. 被引量:8
  • 2Rodriguez-Galindo, C.; Spunt, S. L.; Pappo, A. S. Med. Pediatr. Oncol. 2003, 40, 276.
  • 3Grier, H. E.; Krailo, M. D.; Tarbell, N. J.; Link, M. P.;Fryer, C. J.; Pritchard, D. J.; Gebhardt, M. C.; Dickman, P. S.; Perlman, E. J.; Meyers, P. A.; Donaldson, S. S.; Moore, S.; Rausen, A. R.; Vietti, T. J.; Miser, J. S. N. Engl. J. Med. 2003, 348, 694.
  • 4Barker, L. M.; Pendergrass, T. W.; Sanders, J. E.; Hawkins, D. S. J. Clin. Oncol. 2005, 23, 4354.
  • 5Chansky, H. A.; Barahmand-Pour, F. Mei, Q.; Kahn- Farooqi, W.; Zielinska-Kwiatkowska, A.; Blackburn, M.; Chansky, K.; Conrad, E. U. 3rd.; Bruckner, J. D.; Greenlee, T. K.; Yang, L. J. Orthop. Res. 2004, 22, 910.
  • 6Hu-Lieskovan, S.; Heidel, J. D.; Bartlett, D. W.; Davis, M. E.; Triche, T. J. Cancer Res. 2005, 65(19), 8984.
  • 7Tirado, O. M.; Mateo-Lozano, S.; Villar, J.; Dettin, L. E.; Llort, A.; Gallego, S.; Ban, J.; Kovar, H.; Notario, V. Cancer Res. 2006, 66(20), 9937.
  • 8Rener, M.; Claesson, M. H.; Bregenholt, S.; Ropke, M. Exp. Clin. lmmunogenet. 1996, 13(1), 30.
  • 9Nijman, H. W.; Houbiers, J. G.; Vierboom, M. P.; van der Burg, S. H.; Drijfhout, J. W.; D'Amaro, J.; Kenemans, P.; Melief, C. J.; Kast, W. M. Eur. J. Immunol. 1993, 23(6), 1215.
  • 10Gulukota, K.; Sidney, J.; Sette, A.; DeLisi, C. J. Mol. Biol. 1997, 267, 1258.

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部